NEOGENOMICS INC Q3 FY2026 earnings call

• Leadership Transition: CEO Tony Zook is stepping down effective January 4, 2027, with President and COO Warren Stone succeeding him as CEO. Zook will become Executive Chair. The transition is described as being executed from a position of strength to ensure continuity.
• Strategic Focus on NGS and MRD: Management emphasizes a shift toward higher-value testing modalities. NGS currently represents one-third of clinical revenue but is expected to approach two-thirds alongside Minimal Residual Disease (MRD) tests over time.
• NGS Growth Drivers: NGS revenue grew 29% with volume growth of 17%. Large-panel test volumes grew over 25%. Growth is attributed to mix shifts toward high-value panels, expanded sales force, and new product launches like the upgraded Neocomplete Heme panel.
• MRD Launch Progress: RadarST received Medicare coverage for immunotherapy monitoring in August, marking the third covered indication. Approximately 30% of RadarST orders are accompanied by other NeoGenomics tests, indicating strong portfolio attachment.
• Operational Excellence: Adjusted gross margins expanded by over 300 basis points to 49%, driven by Average Unit Price (AUP) growth of 11%, favorable product mix, and 'Lab of the Future' efficiencies. The company upgraded its Revenue Cycle Management platform to Zyfin to improve collection rates.
• Digital Transformation: Partnerships with Indica Labs are expanding to leverage AI for digital pathology, aiming to improve operational efficiency and support diagnostic workflows.

Total revenue reached $209 million, an 11% year-over-year increase. Clinical revenue, representing approximately 93% of total revenue, grew 13% to $194 million. Within clinicals, Next-Generation Sequencing (NGS) revenue surged 29%, driven by strong trends in both hematology and solid tumor segments. Non-clinical revenue was $15 million, a decline of approximately 10% or $1.5 million year-over-year, serving as a modest headwind due to the exit of low-margin legacy pharma contracts.

• Full-Year 2026 Revenue Guidance Raised: Increased to $807–$809 million from the previous range of $802–$806 million, implying approximately 11% growth at the midpoint.
• Full-Year 2026 Adjusted EBITDA Guidance Raised: Increased to approximately $60 million from the previous range of $56–$58 million, reflecting nearly 40% year-over-year growth.
• Q4 2026 Expectations: Implied revenue growth of approximately 11% for the fourth quarter. Adjusted gross margin for Q4 is anticipated to be approximately 48%.
• Key Assumptions: Clinical business expected to grow in the low teens; NGS revenue expected to grow more than 25% (approaching $250 million); non-clinical business expected to decline in the low double digits.

• Reimbursement Dependency: Success of the MRD franchise (RadarST) is heavily dependent on securing additional payer reimbursements. Two further indications are under review, with potential approval by mid-2027.
• Legacy Pharma Headwinds: The non-clinical segment faces ongoing declines due to the strategic exit of low-margin, commoditized contracts, which may continue to drag on overall revenue growth.
• Operational Execution Risks: The implementation of the new Zyfin RCM platform caused temporary impacts on receivables, though normalization is expected by early 2027.
• Competitive Pressure: The company operates in a competitive community oncology setting against large central labs, requiring continuous differentiation through integrated portfolios and workflow simplification.

Q: Analyst asked about the timing and rationale for the CEO transition, referencing past leadership instability.

A: CEO Tony Zook stated the transition is planned from a position of strength to ensure continuity. Warren Stone has been involved in strategy for years, ensuring alignment. Unlike past transitions, this allows Stone to own the budget process immediately, avoiding disruption. An investor day is planned for H1 2027 to share long-term ambitions.

Q: Analyst inquired about the sustainability of the 11% AUP growth and whether NGS volume growth came from new vs. existing customers.

A: CFO Abhishek Jain noted that the 11% AUP was boosted by exiting one high-volume, low-value customer. Normalized AUP growth should return to mid-single digits, supported by mix shifts to high-margin NGS and RCM wins. Warren Stone confirmed robust new customer acquisition alongside same-store growth, aided by bidirectional EMR interfaces.

Q: Analyst questioned if MRD adoption is genuine uptake or just trialing, and how attach rates work.

A: Warren Stone highlighted that reordering physicians indicates sticky adoption rather than initial trialing. The attach rate remains consistent at ~30%, broad-based across indications. Andrew Brackman added that the 'halo effect' drives multi-product adoption, with most attachments being to NGS tests rather than just other MRD products.

Q: Analyst asked about the impact of preliminary 2027 Medicare rates on the clinical business and ASP growth.

A: CEO Tony Zook stated exposure to Medicare Part B rate cuts is low (mid-single-digit millions), so it won't significantly hinder AUP growth. However, it will impact EBITDA flow-through, requiring disciplined expense management. CFO Jain agreed that while the absolute number is small relative to AUP growth, it requires creative cost allocation.

Q: Analyst asked about the strategic future of the non-clinical/pharma business and when it might bottom out.

A: CEO Tony Zook clarified they will not pursue low-value bespoke solutions but see potential for slight positive growth in 2027 due to high-margin Oncology Data Solutions (ODS) offsetting legacy pharma declines. The real value lies in supporting next-gen products like WGS in 2028+, where ODS data becomes critical.